Abstract

Asahi Intec Co., Ltd. will report fiscal results on August 14, 2026 after market close; this preview highlights expected double‑digit revenue growth, resilient margins, and EPS trends alongside consensus views on product mix and currency exposure.

Market Forecast

For the current quarter, market expectations point to revenue of 34.82 billion JPY with year-over-year growth of 24.26%, EBIT of 6.59 billion JPY with year-over-year growth of 78.77%, and EPS of 18.17 JPY with year-over-year growth of 77.72%. Margin implications from guidance suggest stable-to-healthy profitability with operational leverage, though explicit gross margin and net margin guidance were not provided; consensus expects EPS expansion to outpace revenue.

Main business momentum is anchored by the Medical Division, supported by stable procedure volumes and product launches. The Device Division is viewed as the most promising segment with revenue of 8.66 billion JPY and accelerating year-over-year expansion from new platform wins and mix upgrade.

Last Quarter Review

Last quarter, Asahi Intec Co., Ltd. delivered revenue of 37.10 billion JPY (up 22.35% YoY), a gross profit margin of 71.37%, GAAP net profit attributable to the parent company of 9.44 billion JPY with a net profit margin of 25.45%, and adjusted EPS of 35.57 JPY (up 376.17% YoY), while net profit grew 17.90% quarter over quarter.

A key highlight was profitability resilience with gross margin above 70% reflecting favorable product mix and manufacturing efficiency. The Medical Division generated 31.67 billion JPY, while the Device Division contributed 8.66 billion JPY; management commentary pointed to continued demand normalization and broader adoption across geographies.

Current Quarter Outlook

Main business: Medical Division revenue durability and mix

The Medical Division remains the core earnings engine, with product breadth in interventional devices and strong installed base usage supporting volume. Given the prior quarter’s gross margin at 71.37%, incremental mix within higher-value catheters and guidewires should help defend margin even if foreign exchange volatility mildly compresses price realization in overseas markets. The unit’s revenue base of 31.67 billion JPY last quarter sets a high bar, yet procedural growth and international expansion suggest the segment can maintain mid- to high-teens growth while contributing significantly to EBIT leverage this quarter.

Most promising business: Device Division operating leverage

The Device Division’s 8.66 billion JPY last quarter underscores expanding demand from OEM partners and platform content growth. With the company-wide EBIT forecast up 78.77% YoY to 6.59 billion JPY on 24.26% revenue growth, operating leverage is likely to be evident in this division where fixed-cost absorption and yield gains can magnify profitability. Key watch items this quarter include new program ramps, order cadence from global customers, and any commentary on capacity utilization, as these determine whether the division can outgrow the consolidated topline and extend its contribution margin.

Stock price sensitivities this quarter

Investors are likely to focus on the relationship between revenue growth and EPS acceleration, as consensus implies significant margin expansion through operating leverage. Any deviation in gross margin versus the last quarter’s 71.37%—especially if mix skews to premium medical devices—could shift EPS by an outsized amount relative to revenue. Currency dynamics against the Japanese yen and the timing of OEM program ramps in the Device Division also remain pivotal for near-term valuation multiples.

Analyst Opinions

Bullish opinions dominate recent commentary, emphasizing sustained double-digit revenue growth and notable EPS acceleration supported by operating leverage and stable gross margins. Analysts point to the Medical Division’s consistent performance and the Device Division’s upside from program launches as near-term catalysts, and they expect the company to deliver on revenue of roughly 34.82 billion JPY with year-over-year growth above 20%, alongside EBIT growth near 80%. The prevailing view is that consensus estimates are achievable given last quarter’s outperformance on revenue and EPS and the visibility from core product demand and OEM pipelines.